REG - Arecor Therapeutics - Grant of LTIP Options and PDMR Dealing
06/12/2022 16:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221206:nRSF8052Ia&default-theme=true
RNS Number : 8052I Arecor Therapeutics PLC 06 December 2022
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Grant of LTIP Options and PDMR Dealing
Cambridge, UK, 6 December 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier
lives, announces that on 5 December 2022, it granted a total of 270,000
options under the Company's Long Term Incentive Plan ("LTIP Options") over new
ordinary shares of 1p each in the Company ("Ordinary Shares").
The LTIP Options have an exercise price of 1p and are granted to Senior
Management (persons discharging managerial responsibilities ("PDMRs") of the
Company. Performance conditions include commercial objectives and Total
Shareholder Return during the three-year performance period.
The LTIP Options are subject to continued service and the extent to which the
performance conditions are satisfied. Vested LTIP Options will normally be
exercisable until the tenth anniversary of the grant date, after which time
they will lapse. They are subject to a condition that the LTIP Options or the
Ordinary Shares acquired on exercise of the LTIP Options (other than those
sold to cover tax and National Insurance) are held for a minimum one-year
period from vesting.
The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.
For further information, please contact:
Arecor Therapeutics plc www.arecor.com (http://www.arecor.com/)
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:sarah.howell@arecor.com)
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:info@arecor.com)
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)
Panmure Gordon (UK) Limited Tel: +44 (0) 20 7886 2500
(NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat ™
platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
(http://www.arecor.com/)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Shafiq Choudhary
2. Reason for the notification
a) Position/status: Managing Director, Tetris Pharma Ltd
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s):
Exercise Price(s) Volume(s)
0.01 50,000
d) Aggregated information:
· Aggregated volume: 50,000
· Price: N/A
e) Date of the transaction: 5 December 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
50,000
N/A
e)
Date of the transaction:
5 December 2022
f)
Place of the transaction:
Outside of a trading venue
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: David Gerring
2. Reason for the notification
a) Position/status: VP Development
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s):
Exercise Price(s) Volume(s)
0.01 20,000
d) Aggregated information:
· Aggregated volume: 20,000
· Price: N/A
e) Date of the transaction: 5 December 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
20,000
N/A
e)
Date of the transaction:
5 December 2022
f)
Place of the transaction:
Outside of a trading venue
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Sarah Howell
2. Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s):
Exercise Price(s) Volume(s)
0.01 80,000
d) Aggregated information:
· Aggregated volume: 80,000
· Price: N/A
e) Date of the transaction: 5 December 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
80,000
N/A
e)
Date of the transaction:
5 December 2022
f)
Place of the transaction:
Outside of a trading venue
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Jane Jezek
2. Reason for the notification
a) Position/status: Chief Scientific Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s):
Exercise Price(s) Volume(s)
0.01 40,000
d) Aggregated information:
· Aggregated volume: 40,000
· Price: N/A
e) Date of the transaction: 5 December 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
40,000
N/A
e)
Date of the transaction:
5 December 2022
f)
Place of the transaction:
Outside of a trading venue
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Fiona Lawrence
2. Reason for the notification
a) Position/status: VP Clinical & Regulatory Affairs and QA
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s):
Exercise Price(s) Volume(s)
0.01 16,667
d) Aggregated information:
· Aggregated volume: 16,667
· Price: N/A
e) Date of the transaction: 5 December 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
16,667
N/A
e)
Date of the transaction:
5 December 2022
f)
Place of the transaction:
Outside of a trading venue
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Susan Lowther
2. Reason for the notification
a) Position/status: Chief Financial Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s):
Exercise Price(s) Volume(s)
0.01 63,333
d) Aggregated information:
· Aggregated volume: 63,333
· Price: N/A
e) Date of the transaction: 5 December 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
63,333
N/A
e)
Date of the transaction:
5 December 2022
f)
Place of the transaction:
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUPGGUPUPPGQQRecent news on Arecor Therapeutics
See all newsREG - Arecor Therapeutics - BOARD CHANGE
AnnouncementREG - Arecor Therapeutics - Arecor and TRx Biosciences research collaboration
AnnouncementRCS - Arecor Therapeutics - Arecor and TRx Biosciences research collaboration
AnnouncementREG - Arecor Therapeutics - Arecor announces launch of Ogluo® in Netherlands
AnnouncementREG - Arecor Therapeutics - Year End Trading Update
Announcement